Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Samer S. AlMasri

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9403-7503; OpenAlex author ID A5033632239. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 4 papers · 2024: 2 papers

Papers 8

  1. Postoperative infectious complications worsen oncologic outcomes following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.27595↗
  2. Impact of Neoadjuvant Therapy on Oncological Outcomes of Patients With Distal Pancreatic Adenocarcinoma. Co-author DOI 10.1002/jso.27856↗
  3. The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. Co-author DOI 10.1016/j.hpb.2022.12.002↗
  4. No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.01.016↗
  5. Obesity Is Associated With Increased Risk for Adverse Postoperative Outcomes After Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jss.2022.11.050↗
  6. Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2023.7070↗
  7. Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2022.18355↗
  8. Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adenocarcinoma. First author DOI 10.1002/jso.26510↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Amer H. Zureikat · 8 shared papers, 2021–2024 · strength 1.33
  2. Alessandro Paniccia · 8 shared papers, 2021–2024 · strength 1.33
  3. Hussein H. Khachfe · 5 shared papers, 2023–2024 · strength 0.90
  4. Aatur Dilip Singhi · 5 shared papers, 2022–2024 · strength 0.82
  5. Ibrahim Nassour · 5 shared papers, 2021–2024 · strength 0.81
  6. Nathan Bahary · 5 shared papers, 2021–2023 · strength 0.73
  7. Sowmya Narayanan · 2 shared papers, 2021–2024 · strength 0.32
  8. Asmita Chopra · 2 shared papers, 2021–2024 · strength 0.32
  9. Hao Liu · 2 shared papers, 2023 · strength 0.31
  10. Caroline J. Rieser · 2 shared papers, 2021–2023 · strength 0.26
  11. Hao Liu · 1 shared paper, 2024 · strength 0.20
  12. Anthony Gebran · 1 shared paper, 2024 · strength 0.20
  13. Pranav Murthy · 1 shared paper, 2023 · strength 0.17
  14. Michael T. Lotze · 1 shared paper, 2023 · strength 0.17
  15. Melissa Ellen Hogg · 1 shared paper, 2022 · strength 0.14
  16. Hao Liu · 1 shared paper, 2022 · strength 0.14
  17. Herbert J. Zeh · 1 shared paper, 2022 · strength 0.14
  18. Brian A. Boone · 1 shared paper, 2022 · strength 0.14
  19. David L. Bartlett · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.